A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT04660799 · COMPLETED
Trial details
- NCT number
- NCT04660799
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-24
- Primary completion
- 2022-05-23
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.